Funding
>
Latest News
Abcuro Secures $200 Million in Series C Funding to Advance Ulviprubart for Inclusion Body Myositis
February 12th 2025
Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.
